Infinity Pharmaceuticals, Inc. (INFI)
$0.008
Rating:
Recommendation:
Neutral
| Symbol | INFI |
|---|---|
| Price | $0.008 |
| Beta | 1.380 |
| Volume Avg. | 3.98M |
| Market Cap | 0.726M |
| Shares () | - |
| 52 Week Range | 0.0056-1.3 |
| 1y Target Est | - |
| DCF Unlevered | INFI DCF -> | |
|---|---|---|
| DCF Levered | INFI LDCF -> | |
| ROE | 166.89% | Strong Buy |
| ROA | -187.96% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | -1.69% | Neutral |
| P/E | -0.02 | Neutral |
| P/B | -0.02 | Neutral |
Latest INFI news
About
Download (Excel)Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Cambridge, Massachusetts.